Drug Trial Radar · NCT05947500
Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial
Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
May 21, 2024
Primary completion
Jan 1, 2028
Study completion Jan 1, 2028
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- First posted
- Jul 17, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, which is an enzyme that plays a role in repair of damaged deoxyribonucleic acid (DNA) as well as tumor cell replication and survival. It may lead to tumor cell death by inhibiting ATR kinase activity. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tuvusertib in combination with avelumab may lengthen the time before Merkel cell cancer starts getting worse compared to giving avelumab alone.
Conditions
- Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
- Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
- Locally Advanced Merkel Cell Carcinoma
- Metastatic Merkel Cell Carcinoma
- Refractory Merkel Cell Carcinoma
- Unresectable Merkel Cell Carcinoma
Interventions
AvelumabDrug
Given IV
Biopsy ProcedureProcedure
Undergo biopsy
Biospecimen CollectionProcedure
Undergo collection of blood and stool
Computed TomographyProcedure
Undergo CT or PET/CT
Magnetic Resonance ImagingProcedure
Undergo MRI
Positron Emission TomographyProcedure
Undergo PET/CT
TuvusertibDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite progression-free survival (PFS)Time frame: From registration to progressive disease or death whichever occurs first, assessed up to 2 years
Locations
51 sites in 2 countries. Site status is shown where the registry gives one.
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care
Irvine, California
UC San Diego Moores Cancer Center
La Jolla, California
Keck Medicine of USC Koreatown
Los Angeles, California
Los Angeles General Medical Center
Los Angeles, California
USC / Norris Comprehensive Cancer Center
Los Angeles, California
USC Norris Oncology/Hematology-Newport Beach
Newport Beach, California
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
UCHealth University of Colorado Hospital
Aurora, Colorado
Yale University
New Haven, Connecticut
Sibley Memorial Hospital
Washington D.C., District of Columbia
UM Sylvester Comprehensive Cancer Center at Aventura
Aventura, Florida
UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida
UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida
UM Sylvester Comprehensive Cancer Center at Kendall
Miami, Florida
UM Sylvester Comprehensive Cancer Center at Plantation
Plantation, Florida
Moffitt Cancer Center - McKinley Campus
Tampa, Florida
Moffitt Cancer Center
Tampa, Florida
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Memorial Hospital East
Shiloh, Illinois
HaysMed
Hays, Kansas
University of Kansas Cancer Center
Kansas City, Kansas
Lawrence Memorial Hospital
Lawrence, Kansas
The University of Kansas Cancer Center - Olathe
Olathe, Kansas
University of Kansas Cancer Center-Overland Park
Overland Park, Kansas
University of Kansas Hospital-Indian Creek Campus
Overland Park, Kansas
Salina Regional Health Center
Salina, Kansas
University of Kansas Health System Saint Francis Campus
Topeka, Kansas
University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas
Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland
Dana-Farber Cancer Institute
Boston, Massachusetts
Siteman Cancer Center at Saint Peters Hospital
City of Saint Peters, Missouri
Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri
University Health Truman Medical Center
Kansas City, Missouri
University of Kansas Cancer Center - North
Kansas City, Missouri
University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri
Washington University School of Medicine
St Louis, Missouri
Siteman Cancer Center-South County
St Louis, Missouri
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.